Charles Grassley news from FiercePharma
NewsU.S. Paxil probe broadens
More government watchdogs appear to be boarding the Paxil investigation train. The Justice Department is coordinating a probe that includes Colorado's Justice folks and the Boston U.S. attorney's Read more...
Grassley asks FDA for Paxil review
Seemingly tireless FDA critique-man Sen. Charles Grassley now has his eye on GlaxoSmithKline. He's asking the FDA to review GSK's antidepressant Paxil, which just emerged from a years-long probe in Read more...
Pfizer strikes back with Chantix adsHit by new concerns about the safety of its stop-smoking drug Chantix, Pfizer is hitting back with an advertising and PR campaign. And no wonder: The drugmaker has been counting on that drug, with Read more...JAMA: Merck paid docs for bylines
Merck wrote its own articles on Vioxx research and then paid prestigious doctors to append their bylines, according to a new story in the Journal of the American Medical Association. Of course, Read more...
Arms twisted, pharma promises disclosure
Pharma knows that self-regulation is the best kind. That's why 12 drug and device makers have promised Sen. Chuck Grassley that they are working on plans to disclose CME grants. You know, the money Read more...
Seroquel researcher got cash from AZ
Sen. Charles Grassley's hall of shame: The chairman of the Senate Finance Committee, who's been trying to rally support for a bill requiring drug and device makers to disclose anything of value Read more...
Congress: M/S-P sat on bad news
The Vytorin onslaught continues, with Congressional committees circling and secret emails surfacing. And Merck and Schering-Plough, looking to minimize the damage, are criticizing the American Read more...
GAO to probe FDA's post-market follow-up
The government's own watchdog will soon be sniffing around FDA drug approvals and FDA-ordered post-marketing studies. Prompted by Sen. Charles Grassley, the Government Accountability Office plans to Read more...
Grassley takes aim at Prodisc
Yet another medical device maker has been called on the Congressional carpet. Sen. Charles Grassley is asking Synthes, which makes an artificial spinal disk known as Prodisc, whether doctors whose Read more...
Congress: Were Enhance results secret?
Finally, someone asked the question we've been wanting to ask ourselves: Even if the Enhance study data remained blinded, could Merck or Schering-Plough have divined its overall sway? Sen. Charles Read more...
| Press ReleasesPRESS RELEASE: Floor Statement of U.S. Senator Chuck Grassley Floor Statement of U.S. Senator Chuck Grassley of Iowa Ranking Member of the Committee on Finance Intimidation of Scientists WASHINGTON, Nov. 16, 2007--Sen. Chuck Grassley has released a floor Read more... |
Get more Charles Grassley coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends